First-line<i>Helicobacter pylori</i>eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis

<jats:sec><jats:title>Objective</jats:title><jats:p>To determine the optimal regimen of different first-line<jats:italic>Helicobacter pylori</jats:italic>eradication therapies according to the clarithromycin resistance rate.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Electronic search for articles published between January 2005 and April 2016. Randomised, controlled trials that reported the effectiveness of first-line eradication therapies in treatment-naïve adults were included. Two independent reviewers performed articles screening and data extraction. Network and traditional meta-analyses were conducted using the random effect model. Subgroup analyses were performed to determine the ranking of regimens in countries with high (>15%) and low (<15%) clarithromycin resistance. Data including adverse events and therapeutic cure rate were also extracted and analysed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>117 trials (totally 32 852 patients) for 17<jats:italic>H. pylori</jats:italic>eradication regimens were eligible for inclusion. Compared with 7-day clarithromycin-based triple therapy, sequential therapy (ST) for 14 days had the highest effectiveness (OR=3.74, 95% CrI 2.37 to 5.96). ST-14 (OR=6.53, 95% CrI 3.23 to 13.63) and hybrid therapy (HY) for 10 days or more (OR=2.85, 95% CrI 1.58 to 5.37) represented the most effective regimen in areas with high and low clarithromycin resistance, respectively. The effectiveness of standard triple therapy was below therapeutic eradication rate in most of the countries. Longer duration was associated with higher eradication rate, but with a higher risk of events that lead to discontinuation.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>ST and HY appeared to be the most effective therapies in countries with high and low clarithromycin resistance, respectively. The clinical decision for optimal regimen can be supported by referring to the rank ordering of relative efficacies stratified by local eradication rates, antibiotic resistance and safety profile.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>CRD42015025445.</jats:p></jats:sec>